Identifying alterations in the p53/MDM2/p14ARF pathway would make it possible to obtain an early molecular diagnosis and a prognostic prediction, and would facilitate the administration of the most appropriate treatments for each neuroblastoma patient. The gene discussed is MDM2; the disease is neuroblastoma.